Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 | P08588 | 5/20 | 1.00 |
| ▸ | HTR1A | P08908 | 6/20 | 0.67 |
| ▸ | HTR2C | P28335 | 3/20 | 0.67 |
| ▸ | HTR1D | P28221 | 1/20 | 0.67 |
| ▸ | HTR1B | P28222 | 1/20 | 0.67 |
| ▸ | HTR3A | P46098 | 3/20 | 0.66 |
| ▸ | HTR3E | A5X5Y0 | 2/20 | 0.66 |
| ▸ | HTR3B | O95264 | 2/20 | 0.66 |
| ▸ | HTR3D | Q70Z44 | 2/20 | 0.66 |
| ▸ | HTR3C | Q8WXA8 | 2/20 | 0.66 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.66 |
| ▸ | HTR7 | P34969 | 6/20 | 0.63 |
| ▸ | NPC1 | O15118 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | HTR2A | P28223 | 3/20 | 0.59 |
| ▸ | HTR6 | P50406 | 3/20 | 0.59 |
| ▸ | HTR2B | P41595 | 2/20 | 0.59 |
| ▸ | TP53 | P04637 | 1/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7838014 | 1.00 | ADRB1 (1.00) | ADRB1HTR1AHTR2CHTR1DHTR1B | |
| Bromide SCHEMBL27617608 | 0.98 | ADRB1 (0.97) | ADRB1HTR1AHTR2CHTR1DHTR1B | |
| Piperazine SCHEMBL28092166 | 0.98 | ADRB1 (0.97) | ADRB1HTR1AHTR2CHTR1DHTR1B | |
| Hydrochloric Acid SCHEMBL1706127 | 0.98 | ADRB1 (0.97) | ADRB1HTR1AHTR2CHTR1DHTR1B | |
| SCHEMBL5669070 | 0.98 | ADRB1 (0.97) | ADRB1HTR1AHTR2CHTR1DHTR1B | |
| Bromide SCHEMBL4875933 | 0.98 | ADRB1 (0.97) | ADRB1HTR1AHTR2CHTR1DHTR1B | |
| Hydrochloric Acid SCHEMBL1024982 | 0.98 | ADRB1 (0.97) | ADRB1HTR1AHTR2CHTR1DHTR1B | |
| Hydrochloric Acid SCHEMBL7757785 | 0.98 | ADRB1 (0.97) | ADRB1HTR1AHTR2CHTR1DHTR1B | |
| SCHEMBL4526848 | 0.94 | ADRB1 (0.88) | ADRB1HTR1AHTR2CHTR1DHTR1B | |
| SCHEMBL11074672 | 0.87 | ADRB1 (0.76) | ADRB1NPC1MAPTCYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1072 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025133248-A1 | DIASTEREOMERIC AMINOALCOHOL AND AMINOETHER SALTS OF 2-[(4R,S)-8-FLUORO-2-[4-(3-METHOXYPHENYL)PIPERAZIN-1-YL]-3-[2-METHOXY-5-(TRIFLUOROMETHYL)PHENYL]-3,4-DIHYDROQUINAZOLIN-4-YL]ACETIC ACID AND THEIR USE FOR ENANTIOMERIC SEPARATION | AIC246 AG & CO. KG (DE) | 2025-06-26 | — | — | WO | claimed |
| CN-119798172-A | Preparation method of Leitemivir key intermediate dihydroquinazoline ester | 仁合益康集团有限公司 | 2025-04-11 | — | — | CN | claimed |
| CN-119330912-A | Fluorescent probe low-dimensional organic-inorganic hybrid halide material for nitrobenzene with high moisture stability and high quantum yield fluorescence | 济宁学院 | 2025-01-21 | — | — | CN | claimed |
| CN-118373778-A | Preparation method of letromycin | 湖北广济医药科技有限公司 | 2024-07-23 | — | — | CN | claimed |
| CN-115850192-A | Process for preparing 3,4-dihydroquinazoline derivatives | 南京正大天晴制药有限公司 | 2023-03-28 | — | — | CN | claimed |
| CN-112831206-B | Inorganic oxide dispersion with controllable water content and preparation method thereof | 凯斯科技股份有限公司 | 2022-12-30 | — | — | CN | claimed |
| CN-111879767-B | Color development test method of piperazine novel mental active substance | 福建警察学院 | 2022-05-03 | — | — | CN | claimed |
| CN-111795963-B | Method for chromogenic detection of piperazine novel psychotropic active substances | 福建警察学院 | 2022-05-03 | — | — | CN | claimed |
| CN-110452130-B | Obovatol Mannich base derivative and preparation method and application thereof | 山西农业大学 | 2022-03-01 | — | — | CN | claimed |
| CN-110437191-B | 13-amino xanthatin derivative and preparation method and application thereof | 山西农业大学 | 2021-05-04 | — | — | CN | claimed |
| EP-1831206-A2 | N-SUBSTITUTED BENZIMIDAZOLYL C-KIT INHIBITORS AND COMBINATORIAL BENZIMIDAZOLE LIBRARY | OSI Pharmaceuticals, Inc. (US) | 2007-09-12 | — | — | EP | claimed |
| WO-2006133822-A1 | METHOD FOR PRODUCING DIHYDROQUINAZOLINES | BAYER HEALTHCARE AG (DE) | 2006-12-21 | — | — | WO | claimed |
| WO-2006060381-A2 | N-SUBSTITUTED BENZIMIDAZOLYL C-KIT INHIBITORS AND COMBINATORIAL BENZIMIDAZOLE LIBRARY | OSI PHARMACEUTICALS, INC. (US) | 2006-06-08 | — | — | WO | claimed |
| US-20060116402-A1 | N-substituted benzimidazolyl c-Kit inhibitors and combinatorial benzimidazole library | OSI PHARMACEUTICALS, INC. | 2006-06-01 | — | — | US | claimed |
| CN-1662516-A | N, N-disubstituted diazocycloalkanes | RECORDATI CHEM PHARM (IE) | 2005-08-31 | — | — | CN | claimed |
| CN-1538951-A | Omega-aminoalkylamides of R-2-aryl-propionic acids as inhibitors of chemotaxis of polymorphonucleate and mononucleate cells | ��ķ�ɷ�����˾ | 2004-10-20 | — | — | CN | claimed |
| EP-1077973-A2 | BENZOFURAN DERIVATIVES, PHARMACEUTICAL COMPOSITION CONTAINING THE SAME, AND A PROCESS FOR THE PREPARATION OF THE ACTIVE INGREDIENT | EGIS GYOGYSZERGYAR RT. (HU) | 2001-02-28 | — | — | EP | claimed |
| WO-1999058527-A2 | BENZOFURAN DERIVATIVES, PHARMACEUTICAL COMPOSITION CONTAINING THE SAME, AND A PROCESS FOR THE PREPARATION OF THE ACTIVE INGREDIENT | EGIS Gyógyszergyár Rt. (HU) | 1999-11-18 | — | — | WO | claimed |
| EP-0445811-B1 | Nitrogen-containing heterocyclic compounds, their production and use | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1995-06-14 | — | — | EP | claimed |
| EP-0539180-A1 | Antiviral agents | SANWA KAGAKU KENKYUSHO CO., LTD. (JP) | 1993-04-28 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060116402-A1 | N-substituted benzimidazolyl c-Kit inhibitors and combinatorial benzimidazole library | KIT, CHUK, TNNI3K | ADRB1 3656/4885HTR1A 4095/4885HTR2C 3698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.